MR in phenylketonuria-related brain lesions

Acta Radiologica

Volumn 42, Issue 5, 2001, Pages 459-466

  Dezortova M ^a   Hájek, Milan ^a   Tintera J ^a   Hejcmanova L ^b   Sykova E ^b,c  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Brain, phenylketonuria; MR imaging, diffusion; Spectroscopy

Indexed keywords

CHOLINE; WATER;

ADULT; ARTICLE; BRAIN; BRAIN LEVEL; DIFFUSION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PHENYLKETONURIA;

ADULT; BRAIN; BRAIN CHEMISTRY; CHOLINE; DIFFUSION; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; PHENYLKETONURIAS; WATER;

EID: 0347138015     PISSN: 02841851     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418501127347179     Document Type: Article

References (34)

1. BATTISTINI S., DE STEFANO N., PARLANTI S. & FEDERICO A.: Unexpected white matter changes in an early treated PKU case and improvement after dietary treatment. Funct. Neurol. 6 (1991), 177.
2. BICK U., ULLRICH K., STÖBER U. et al.: White matter abnormalities in patients with treated hyperphenylalaninaemia. Magnetic resonance relaxometry and proton spectroscopy findings. Eur. J. Pediatr. 152 (1993), 1012.
3. BURRI R., MATTHIEU J. M., VANDEVELDE M., LAZEYRAS F., POSSE S. & HERSCHKOWITZ N.: Brain damage and recovery in hyperphenylalaninemic rats. Dev. Neurosci. 12 (1990), 116.
4. CLEARY M. A., WALTER J. H., WRAITH J. E., WHITE F., TYLER K. & JENKINS J. P.: Magnetic resonance imaging in phenylketonuria. Reversal of cerebral white matter change. J. Pediatr. 127 (1995), 251.
5. DANIELSEN E. R. & HENRIKSEN O.: Absolute quantitative proton NMR spectroscopy based on the amplitude of the local water suppression pulse. Quantitation of brain water and metabolites. NMR Biomed. 7 (1994), 311.
6. DEZORTOVÁ M., HÁJEK M. & HEJCMANOVÁ L.: Decreasing choline signal - A marker of phenylketonuria? Magma 4 (1996), 181.
7. FORSSMAN H., KRISTENSSON K., SOURANDER P. & SVENNERHOLM L.: Histological and chemical studies of a case of phenylketonuria with long survival. J. Ment. Defic. Res. 11 (1967), 194.
8. FULLERTON G. D. & CAMERON I. L.: Relaxation of biological tissues. In: Biological magnetic resonance imaging, p. 115. Edited by F. W. Wehrli et al. VCH Publishers, New York 1988.
9. HÁJEK M., BURIAN M. & DEZORTOVÁ M.: Application of LCModel for quality control and quantitative in vivo 1H MR spectroscopy by short echo time STEAM sequence. Magma 10 (2000), 6.
10. HÁJEK M., HEJCMANOVÁ L. & PRADNY J.: Proton in vivo spectroscopy of patients with hyperphenylalaninaemia. Neuropediatrics 24 (1993), 111.
11. HEID O. & WEBER J.: Diffusion tensor trace pulse sequences. In: Proceedings 5th ISMRM Meeting (1997), p. 225.
12. HUETHER G., NEUHOFF V. & KAUS R.: Brain development in experimental hyperphenylalaninemia. Disturbed proliferation and reduced cell numbers in the cerebellum. Neuropediatrics 14 (1983), 12.
13. JOHANNIK K., VAN HECKE P., FRANCOIS B. et al.: Localized brain proton NMR spectroscopy in young adult phenylketonuria patients. Magn. Reson. Med. 31 (1994), 53.
14. KORNGUTH S., ANDERSON M., MARKLEY J. L. & SHEDLOVSKY A.: Near-microscopic magnetic resonance imaging of the brains of phenylalanine hydroxylase-deficient mice, normal littermates, and of normal BALB/c mice at 9.4 T. Neuroimage 1 (1994), 220.
15. KORNGUTH S., GILBERT-BARNESS E., LANGER E. & HEGSTRAND L.: Golgi-Kopsch silver study of the brain of a patient with untreated phenylketonuria, seizures and cortical blindness. Am. J. Med. Genet. 44 (1992), 443.
16. KREIS R., FUSCH C. & BOESCH C.: In vivo characterization of three water compartments in human white matter using a single voxel technique with short TE. In: Proceedings 11th SMRM Meeting (1992), p. 1963.
17. KREIS R., PIETZ J., PENZIEN J., HERSCHKOWITZ N. & BOESCH C.: Identification and quantitation of phenylalanine in the brain of patients with phenylketonuria by means of localized in vivo 1H magnetic-resonance spectroscopy. J. Magn. Reson. Series B 107 (1995), 242.
18. LE BIHAN D., TURNER R. & PATRONAS A.: Diffusion MR imaging in normal brain and in brain tumors. In: Diffusion and perfusion magnetic resonance imaging. Application to functional MRI, p. 134. Edited by D. Le Bihan. Raven Press, New York 1995.
19. LEUZZI V. GUALDI G. F., FABBRIZI F., TRASIMENI G., DI BIASI C. & ANTONOZZI I.: Neuroradiological (MRI) abnormalities in phenylketonuric subjects. Clinical and biochemical correlations. Neuropediatrics 24 (1993), 302.
20. MALAMUD N.: Neuropathology of phenylketonuria. J. Neuropathol. Exp. Neurol. 25 (1966), 254.
21. MÖLLER H. E., VERMATHEN P., ULLRICH K., WEGLAGE J., KOCH H.-G. & PETERS P. E.: In-vivo NMR spectroscopy in patients with phenylketonuria. Changes of cerebral phenylalanine levels under dietary treatment. Neuropediatrics 26 (1995), 199.
22. NEIL J. J.: Measurement of water motion (apparent diffusion) in biological systems. Concepts Magn. Reson. 9 (1997), 385.
23. NOVOTNY E. J. JR, AVISON M. J., HERSCHKOWITZ N. et al.: In vivo measurement of phenylalanine in human brain by proton nuclear magnetic resonance spectroscopy. Pediatric Res. 37 (1995), 244.
24. PEARSEN K. D. GEAN-MARTON A. D., LEVY H. L. & DAVIS K. R.: Phenylketonuria. MR imaging of the brain with clinical correlation. Radiology 177 (1990), 437.
25. PIETZ J., KKEIS R., SCHMIDT H., MEYDING-LAMADÉ U. K., RUPP A. & BOESCH C.: Phenylketonuria. Findings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment. Radiology 201 (1996), 413.
26. POTEMPSKA A., LOO Y. H. & WISNIEWSKI H. M.: On the possible mechanism of phenylacetate neurotoxicity. Inhibition of choline acetyltransferase by phenylacetyl-CoA. J. Neurochem. 42 (1984), 1499.
27. PROVENCHER S. W.: Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 30 (1993), 672.
28. REYNOLDS R., BURRI R. & HERSCHKOWITZ N.: Retarded development of neurons and oligodendroglia in rat forebrain produced by hyperphenylalaninemia results in permanent deficits in myelin despite long recovery periods. Exp. Neurol. 124 (1993), 357.
29. SHAW D. W. W., MARAVILLA K. R., WEINBERGER E., GARRETSON J., TRAHMS C. M. & SCOTT C. R.: MR imaging of phenylketonuria. AJNR 12 (1991), 403.
30. SWAIMAN K. F. & WU S. R.: Phenylalanine and phenylacetate adversely affect developing mammalian brain neurons. Neurology 34 (1984), 1246.
31. THOMPSON A. J., TILLOTSON S., SMITH I., KENDALL B. E., MOORE S. G. & BRENTON D.: Brain MRI changes in phenylketonuria. Associations with dietary status. Brain 116 (1993), 811.
32. VAN DER KNAAP M. S. & VALK J.: Magnetic resonance of myelin, myelination, and myelin disorders, p. 192. Springer, Berlin 1995.
33. VORISEK I. & SYKOVA E.: Evolution of anisotropic diffusion in the developing rat corpus callosum. J. Neurophysiol. 78 (1997), 912.
34. WEGLAGE J., SCHUIERER G., KURLEMANN G., BICK R. & ULLRICH K.: Different degrees of white matter abnormalities in untreated phenylketonurics. Findings in magnetic resonance imaging. J. Inherit. Metab. Dis. 16 (1993), 1047.